NXTS.US Nexentis Technologies Inc.
- Market cap
- USD 1.05M
- P/E
- -
- P/B
- 0.55x
- ROE
- -1,860.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NXTS.US undervalued?
Graham numberThe Graham number of Nexentis Technologies Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nexentis Technologies Inc. fundamental analysis
No fundamental analysis for Nexentis Technologies Inc. yet.
Nexentis Technologies Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nexentis Technologies Inc.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational ch…
Full company profileNexentis Technologies Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nexentis Technologies Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 322K | 344K | 427K | 176K | 232K | 438K | 394K | 263K | 210K | 0.00 | 0.00 |
| Gross Profit | 76.0K | 202K | 290K | 3.92K | 144K | 244K | 206K | 187K | 33.0K | -79.0K | -418K |
| Operating Income | -938K | -694K | -482K | -1.93M | -1.35M | -4.54M | -5.71M | -7.30M | -4.05M | -4.23M | -19.6M |
| EBITDA | -918K | -677K | -443K | -1.90M | -1.30M | -4.48M | -5.66M | -7.28M | -4.03M | -3.43M | -17.4M |
| Net Income | -599K | -672K | -357K | -1.97M | -1.59M | -4.82M | -5.74M | -6.52M | -5.19M | -4.00M | -35.5M |
| EPS | -1,698 | -743 | -92 | -339 | -257 | -504 | -402 | -190 | -6,797 | -762 | -1,520 |
| Balance Sheet | |||||||||||
| Total Assets | 439K | 535K | 859K | 665K | 688K | 7.60M | 6.49M | 7.24M | 5.47M | 20.4M | 18.7M |
| Total Liabilities | 1.28M | 1.27M | 648K | 1.07M | 1.15M | 1.18M | 755K | 786K | 892K | 4.68M | 16.9M |
| Shareholders' Equity | -562K | -439K | 218K | -381K | -436K | 6.48M | 5.85M | 6.48M | 4.75M | 16.0M | 1.91M |
| Cash & Short-term Investments | 4.51K | 28.3K | 440K | 329K | 265K | 6.81M | 5.75M | 4.48M | 2.52M | 4.07M | 8.88M |
| Total Debt | 497K | 460K | 61.1K | 360K | 234K | 226K | 146K | 54.9K | 7.00K | 992K | 426K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -651K | -623K | -506K | -1.24M | -799K | -4.10M | -5.10M | -3.23M | -3.42M | -3.81M | -4.02M |
| Capital Expenditure | 0.00 | 54.5K | 2.53K | 23.3K | 0.00 | 67.8K | 51.7K | 1.00 | 0.00 | 14.0K | 148K |
| Free Cash Flow | -651K | -678K | -509K | -1.27M | -799K | -4.17M | -5.15M | -3.23M | -3.42M | -3.82M | -4.16M |
| Ratios | |||||||||||
| ROE | - | - | -163.5% | - | - | -74.4% | -98.2% | -100.7% | -109.3% | -25.0% | -1,860.9% |
| ROA | -136.6% | -125.5% | -41.5% | -296.6% | -231.7% | -63.5% | -88.4% | -90.0% | -95.0% | -19.6% | -189.7% |
| Net Profit Margin | -186.2% | -195.4% | -83.7% | -1,121.3% | -685.9% | -1,100.2% | -1,456.7% | -2,475.8% | -2,472.9% | - | - |
| Debt to Equity | - | - | 0.28x | - | - | 0.03x | 0.03x | 0.01x | 0.00x | 0.06x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nexentis Technologies Inc. dividends
Nexentis Technologies Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Nov 9, 2026.
Who owns Nexentis Technologies Inc.
- Insiders 9.23%
- Institutions 2.10%
- Public & others 88.67%
- Shares outstanding 475K
- Free float 140K
Top funds holding NXTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 8.20K | 0.35% | 0.00% | Sep 2026 |
Top institutions holding NXTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 45.2K | 3.11% | 0.00% | Jun 2026 |
| Yorkville Advisors Global, LP | 16.4K | 1.13% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 998.00 | 0.07% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 736.00 | 0.05% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 32.00 | 0.00% | +300.00% | Jun 2026 |
| Barclays PLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
Nexentis Technologies Inc. company profile
- Company name
- Nexentis Technologies Inc.
- Ticker
- NXTS.US
- Exchange
- USA Stocks
- Listed since
- Oct 18, 2017
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Employees
- 7
- Fiscal year end
- December
- Address
- Pinhas Sapir St. 3, Ness Ziona, Israel, 7403626
- Phone
- 347 468 9583
- Website
- nexentistech.com
About Nexentis Technologies Inc.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Nexentis Technologies Inc. management
3- Mr. David PalachChief Executive Officer · born 1966
- Ms. Lital BardaCFO, Financial Controller, Treasurer & Secretary · born 1987
- Ms. Galit KenigsbergHead of Sustainability Operations of scientific advisory board